Cytodyn Inc (CYDY)

[Monroe1]

My question to the board is two fold.

1. Do you think Grip has left or is hedging as the Big Grass Hopper1? Would be a typical pigeon maneuver.

2. "..... in combination with Resmetirom, a drug recently approved by the FDA. The study will evaluate leronlimab’s potential role in preventing and/or reversing liver fibrosis." will end up as a full collaboration with/in combination with Resmetirom, a drug recently approved by the FDA along with breakthrough designation, fast track, and priority review. The study will evaluate leronlimab’s potential role in preventing and/or reversing liver fibrosis.The FDA granted the approval of Rezdiffra to Madrigal Pharmaceuticals.[2] Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis.[1] It is a thyroid hormone receptor beta (NR1A2) agonist.[1]

It does have side effects and some have to stop using it. A combo pill with leronlimab might just fit the bill. Watch it happen.The horses have left the starting gate. Good job CytoDyn Team. $CYDY$ 2024